| pubmed-article:4041333 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:4041333 | lifeskim:mentions | umls-concept:C0019004 | lld:lifeskim |
| pubmed-article:4041333 | lifeskim:mentions | umls-concept:C1524112 | lld:lifeskim |
| pubmed-article:4041333 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:4041333 | lifeskim:mentions | umls-concept:C0028066 | lld:lifeskim |
| pubmed-article:4041333 | lifeskim:mentions | umls-concept:C0001721 | lld:lifeskim |
| pubmed-article:4041333 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:4041333 | pubmed:dateCreated | 1985-11-5 | lld:pubmed |
| pubmed-article:4041333 | pubmed:abstractText | To establish dosage recommendations in patients with end-stage renal disease undergoing chronic haemodialysis, nifedipine kinetics were studied between and during haemodialysis sessions. In eight patients, during the interdialytic period, peak plasma concentrations of nifedipine (29-332 ng/ml) were reached 0.5-1.0 h after administration of a single 10 mg oral dose. Elimination half-life and oral plasma clearance were respectively 2.6 +/- 0.5 h and 1 176 +/- 412 ml/min. Nifedipine plasma protein binding was decreased in uraemic patients (88.8 +/- 0.3% vs 94.4 +/- 0.1%) but not affected by haemodialysis. Removal by haemodialysis was low: the dialyser extraction ratio and the dialysis clearance were respectively 2.3 +/- 0.8% and 2.8 +/- 0.9 ml/min. | lld:pubmed |
| pubmed-article:4041333 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:language | eng | lld:pubmed |
| pubmed-article:4041333 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:4041333 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4041333 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:4041333 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:4041333 | pubmed:issn | 0306-5251 | lld:pubmed |
| pubmed-article:4041333 | pubmed:author | pubmed-author:SinglasEE | lld:pubmed |
| pubmed-article:4041333 | pubmed:author | pubmed-author:JacobsCC | lld:pubmed |
| pubmed-article:4041333 | pubmed:author | pubmed-author:TaburetA MAM | lld:pubmed |
| pubmed-article:4041333 | pubmed:author | pubmed-author:SariRR | lld:pubmed |
| pubmed-article:4041333 | pubmed:author | pubmed-author:MartreHH | lld:pubmed |
| pubmed-article:4041333 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:4041333 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:4041333 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:4041333 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:4041333 | pubmed:pagination | 155-8 | lld:pubmed |
| pubmed-article:4041333 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:meshHeading | pubmed-meshheading:4041333-... | lld:pubmed |
| pubmed-article:4041333 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:4041333 | pubmed:articleTitle | Haemodialysis does not affect the pharmacokinetics of nifedipine. | lld:pubmed |
| pubmed-article:4041333 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:4041333 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:4041333 | lld:pubmed |
